ISRG · CIK 1035267
What Intuitive Surgical, Inc. told the SEC could break it.
Intuitive Surgical's disclosures map a globally distributed supply chain and the trade and regulatory risks at each node. It makes a significant majority of the instruments and accessories it sells at a single facility in Mexicali, Mexico — mostly USMCA-originating and untariffed so far, but a concentration that exposes it to potential Mexico tariffs and single-site risk. It also imports endoscopes made largely in Germany and raw materials and sub-assemblies from China (to support local da Vinci Xi manufacturing there) while selling U.S.-made systems into China — flows it expects to face rising tariffs on in 2026, some already being passed through by suppliers. On top of that, its China business is shaped by provincial healthcare-procurement limits and NMPA approval and quality-system requirements, where additional measures could harm results.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- tariffs on Germany-made endoscopes, China raw materials/sub-assemblies, and US-made systems sold into Chinamedium
Intuitive imports endoscopes (mostly made in Germany), raw materials from China, and sub-assemblies to support local China da Vinci Xi manufacturing, and sells US-made da Vinci Xi systems into China — all subject to tariffs that it expects to increase in 2026 and some suppliers are passing through.
“We also import certain raw materials and finished goods from outside of the U.S. that are subject to tariffs, including our endoscopes, a majority of which are manufactured in Germany. In addition, our operations involve importing certain raw materials from China, importing sub-assemblies to support our local da Vinci Xi surgical system manufacturing in China, and selling U.S.-manufactured da Vinci Xi”
- China provincial healthcare procurement limits and NMPA regulationmedium
China's provincial healthcare-procurement limits and NMPA approval/quality-system requirements affect Intuitive's China business; provincial limits have not been material to date but additional provincial/national measures could harm results.
“Companies providing robotic surgical technology, including our Joint Venture, have been meeting with Chinese government healthcare agencies to discuss these developments and to provide feedback. We cannot assure you that additional provincial or national healthcare”
Geographic concentration
- significant majority of instruments/accessories manufactured in Mexicali, Mexicomedium
Intuitive manufactures a significant majority of the instruments and accessories it sells at its Mexicali, Mexico facility; most qualify as USMCA-originating (untariffed to date), but the concentration creates exposure to potential Mexico import tariffs and single-facility risk.
“potential tariffs on goods imported from Mexico where we manufacture a significant majority of our instruments and accessories that we sell;”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
“The Company's Joint Venture is owned 60% by us and 40% by Fosun Pharma and is located in China. In 2019, the Joint Venture began direct operations for da Vinci products and services in China.”
Cited →“two customers (Intuitive Surgical SARL and Stryker) comprised approximately 29.2% and 15.4%, respectively, of our net sales for the year ended December 31, 2024”
Cited →Baxter International Inc. (Hillrom)
“research and development effort through collaborations with other companies, such as our Integrated Table Motion product offering developed with Hillrom (now a part of Baxter International Inc.).”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch